Skip to Content

Monopar Therapeutics Inc MNPR

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Monopar Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's product pipeline comprises Validive, Camsirubicin, and MNPR-101.

1000 Skokie Boulevard, Suite 350
Wilmette, IL, 60091
T +1 847 388-0349
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type Distressed
Employees 10